BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38290210)

  • 1. Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer.
    Barreto MCA; Treistman N; Cavalcante LBCP; Bulzico D; de Andrade FA; Corbo R; Alves Junior PAG; Vaisman F
    Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38290210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single Radioactive Iodine Treatment Has a Deleterious Effect on Ovarian Reserve in Women with Thyroid Cancer: Results of a Prospective Pilot Study.
    Yaish I; Azem F; Gutfeld O; Silman Z; Serebro M; Sharon O; Shefer G; Limor R; Stern N; Tordjman KM
    Thyroid; 2018 Apr; 28(4):522-527. PubMed ID: 29466932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
    Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study.
    Evranos B; Faki S; Polat SB; Bestepe N; Ersoy R; Cakir B
    Thyroid; 2018 Dec; 28(12):1702-1707. PubMed ID: 30156472
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma.
    Nies M; Cantineau AEP; Arts EGJM; van den Berg MH; van Leeuwen FE; Muller Kobold AC; Klein Hesselink MS; Burgerhof JGM; Brouwers AH; van Dam EWCM; Havekes B; van den Heuvel-Eibrink MM; Corssmit EPM; Kremer LCM; Netea-Maier RT; van der Pal HJH; Peeters RP; Plukker JTM; Ronckers CM; van Santen HM; van der Horst-Schrivers ANA; Tissing WJE; Bocca G; van Dulmen-den Broeder E; Links TP
    Thyroid; 2020 Aug; 30(8):1169-1176. PubMed ID: 32079487
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of Ovarian Reserve with AMH Level in Patients with Well-Differentiated Thyroid Cancer Receiving Radioactive Iodine Ablation Treatment.
    Acıbucu F; Acıbucu DO; Akkar ÖB; Dokmetas HS
    Exp Clin Endocrinol Diabetes; 2016 Nov; 124(10):593-596. PubMed ID: 27711957
    [No Abstract]   [Full Text] [Related]  

  • 7. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
    Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
    Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer.
    Giusti M; Mittica M; Comite P; Campana C; Gay S; Mussap M
    Endocrine; 2018 Jun; 60(3):516-523. PubMed ID: 29302874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in anti-Müllerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis.
    Anagnostis P; Florou P; Bosdou JK; Grimbizis GF; Iakovou I; Kolibianakis EM; Goulis DG
    Maturitas; 2021 Jun; 148():40-45. PubMed ID: 34024350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
    Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
    Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer.
    Mittica M; Dotto A; Comina M; Teliti M; Monti E; Giusti M
    Thyroid Res; 2020; 13():1. PubMed ID: 31938042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Predicting Early Release of Thyroid Cancer Patients from the Isolation Room after Radioiodine-131 Treatment.
    Fatima N; Zaman Mu; Zaman A; Zaman U; Tahseen R; Shahid W
    Asian Pac J Cancer Prev; 2016; 17(1):125-9. PubMed ID: 26838196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine.
    Adamska A; Tomczuk-Bobik P; Popławska-Kita AB; Siewko K; Buczyńska A; Szumowski P; Żukowski Ł; Myśliwiec J; Zbucka-Krętowska M; Adamski M; Krętowski AJ
    Endocr Connect; 2021 Oct; 10(10):1283-1290. PubMed ID: 34524978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
    Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
    Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data.
    Duskin-Bitan H; Leibner A; Amitai O; Diker-Cohen T; Hirsch D; Benbassat C; Shimon I; Robenshtok E
    Thyroid; 2019 May; 29(5):683-691. PubMed ID: 31084551
    [No Abstract]   [Full Text] [Related]  

  • 19. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM; Yau S; Lee SH; Leung WM; Law SC
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.